Personalis, Inc. (FRA:04X)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.10B +125.8% |
| Revenue (ttm) | 55.95M -24.7% |
| Net Income | -82.87M |
| EPS | -0.89 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 10.26 |
| Previous Close | 10.69 |
| Day's Range | 10.26 - 10.26 |
| 52-Week Range | 3.66 - 14.34 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Personalis
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.... [Read more]
Financial Performance
In 2025, Personalis's revenue was $69.65 million, a decrease of -17.69% compared to the previous year's $84.61 million. Losses were -$81.27 million, -0.02% less than in 2024.
Financial numbers in USD Financial StatementsNews
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Luxfer Holdings PLC (NYSE – LXFR), Finward Bancorp (Nasdaq – FNWD), Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR)
BALA CYNWYD, Pa., July 27, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)
BALA CYNWYD, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Personalis price target raised to $16.25 from $11 at BTIG
BTIG raised the firm’s price target on Personalis (PSNL) to $16.25 from $11 and keeps a Buy rating on the shares after Tempus AI (TEM) said it will acquire Personalis…
Tempus AI (TEM) Drops on $1.7B Personalis Deal; Needham Analyst Calls the Slide a “Market Misread”
Tempus AI ($TEM) stock fell about 8% on Monday after the health technology company said it will acquire biotechnology company Personalis ($PSNL) in an all-stock deal valued at $1.7 billion. The…
Morgan Stanley sees strategic logic in Personalis deal despite financial hurdles
Morgan Stanley notes that Tempus AI (TEM) announced a definitive agreement to acquire Personalis (PSNL) for $16.25 per share, with the deal expected to close in late 2026 or early…
AI Daily: Tempus AI to acquire Personalis at enterprise value of $1.5B
Catch up on the top artificial intelligence news and commentary by Wall Street analysts on publicly traded companies in the space with this daily recap compiled by The Fly. PERSONALIS…
Midday Fly By: Domino’s reports mixed Q2, Tempus AI to acquire Personalis
The major averages were mixed near noon as stocks look to rebound from last week’s technology-led selloff. Attention is turning to a week of megacap earnings that could determine whether…
Personalis downgraded to Hold from Buy at Needham
Needham downgraded Personalis (PSNL) to Hold from Buy after the company announced an agreement to be acquired by Tempus AI (TEM) for $16.25 per share in stock. The transaction is…
Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink
Tempus AI, a healthcare tech company, is a favorite of investor Cathie Wood. Personalis does cancer testing.
Personalis downgraded to Hold from Buy at Lake Street
Lake Street analyst Thomas Flaten downgraded Personalis (PSNL) to Hold from Buy with a price target of $16.25, up from $11, after Tempus AI (TEM) announced a definitive agreement to…
Tempus to acquire Personalis for $1.5 billion
Tempus AI said on Monday it would acquire Personalis for about $1.5 billion to bringing its cancer test to the AI-enabled precision medicine firm's oncology portfolio.
Tempus AI to acquire Personalis for $16.25 per share
08:31 EDT Tempus AI (TEM) to acquire Personalis (PSNL) for $16.25 per share
Tempus AI to acquire Personalis for $16.25 per share
Tempus AI (TEM) entered into a definitive agreement to acquire Personalis (PSNL). The acquisition will expand Tempus’ capabilities in minimal residual disease and enhance its ability to support patien...
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that it has entered into a defi...
Personalis trading halted, news pending
08:25 EDT Personalis (PSNL) trading halted, news pending
Personalis price target raised to $17 from $12 at Needham
Needham raised the firm’s price target on Personalis (PSNL) to $17 from $12 and keeps a Buy rating on the shares following a blog report that the company has received…
Personalis attracting takeover interest, Street Insider says
Personalis (PSNL) is said to have hired bankers at Centerview and TD Securities and legal counsel at Cooley to review a potential sale after the precision oncology company attracted takeover…
Personalis moves off low after blog claims company exploring possible sale
15:31 EDT Personalis (PSNL) moves off low after blog claims company exploring possible sale
Personalis price target raised to $18 from $10 at TD Cowen
TD Cowen raised the firm’s price target on Personalis (PSNL) to $18 from $10 and keeps a Buy rating on the shares. The firm adjusted targets in the diagnostics group…
Personalis’ NeXT Personal test granted UKCA marking
Personalis (PSNL) has achieved UKCA – United Kingdom Conformity Assessed – marking for its NeXT Personal Dx test. This critical regulatory milestone enables the clinical use of Personalis’ ultrasensit...
Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that it has achieved UKCA (United Kingdom Conformity Assessed) ...
Personalis price target raised to $13 from $9 at Morgan Stanley
Morgan Stanley analyst Kallum Titchmarsh raised the firm’s price target on Personalis (PSNL) to $13 from $9 and keeps an Equal Weight rating on the shares. The firm is updating…
Personalis’ specimen collection kits obtain European Union CE-IVD mark
Personalis (PSNL)’ Personalis EDTA Blood Collection Kit and Personalis cfDNA Blood Collection Kit have obtained Class A CE-IVD marking in compliance with the European Union’s In Vitro Diagnostic Regul...
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that its Personalis EDTA Blood Collection Kit and Personalis cf...